My ePortfolio Register   

AACR 2014 /
Study shows benefits in use of AG-221 in advanced blood cancers

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 1368

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA

At a press conference during AACR 2014, Dr Stein discussed the clinical activity of the cancer metabolism drug AG-221 in advanced blood cancers. 

Read the article for more.


· AACR 2014

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence